Genetically modified mesenchymal stromal cells in cancer therapy

Cytotherapy

Volumn 18, Issue 11, 2016, Pages 1435-1445

  Sage, Elizabeth K ^a   Thakrar, Ricky M ^a,b   Janes, Sam M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GANCICLOVIR; PEMETREXED; PUROMYCIN; RANTES; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VIRUS VECTOR;

CANCER CLASSIFICATION; CANCER PATIENT; CANCER THERAPY; CELL THERAPY; CELLULAR DISTRIBUTION; CLINICAL TRIAL (TOPIC); DIGESTIVE SYSTEM CANCER; DNA MODIFICATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENE TECHNOLOGY; GENE VECTOR; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG METASTASIS; MESENCHYMAL STROMA CELL; MESENCHYMAL STROMA CELL THERAPY; NEOPLASM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; TUMOR MICROENVIRONMENT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; CYTOLOGY; GENE THERAPY; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; NEOPLASMS; WOUND HEALING;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOPLASMS; WOUND HEALING;

EID: 84992381927     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.09.003     Document Type: Review

References (121)

1. [1] Markets and Markets, Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic). Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System)—Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020. 2014 http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html accessed 31.08.16.
2. [2] The Cell and Gene Therapy Catapult, UK Clinical Trials Database 2016 Commentary. https://ct.catapult.org.uk/wp-content/uploads/2016/07/Clinical-trials-database-2016-commentary.pdf, 2016 accessed 31.08.16].
3. [3] Hawkey, C.J., Allez, M., Clark, M.M., Labopin, M., Lindsay, J.O., Ricart, E., et al. Autologous hematopoetic stem cell transplantation for refractory crohn disease: a randomized clinical trial. JAMA 314:23 (2015), 2524–2534.
4. [4] Weiss, D.J., Casaburi, R., Flannery, R., LeRoux-Williams, M., Tashkin, D.P., A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 143:6 (2013), 1590–1598.
5. [5] Simonson, O.E., Mougiakakos, D., Heldring, N., Bassi, G., Johansson, H.J., Dalen, M., et al. In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome. Stem Cells Transl Med 4:10 (2015), 1199–1213.
6. [6] Matthay, M.A., Therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome. Ann Am Thorac Soc, 12(Suppl. 1), 2015 S54–7.
7. [7] Steinberg, G.K., Kondziolka, D., Wechsler, L.R., Lunsford, L.D., Coburn, M.L., Billigen, J.B., et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. Stroke 47:7 (2016), 1817–1824.
8. [8] Gervois, P., Wolfs, E., Ratajczak, J., Dillen, Y., Vangansewinkel, T., Hilkens, P., et al. Stem cell-based therapies for ischemic stroke: preclinical results and the potential of imaging-assisted evaluation of donor cell fate and mechanisms of brain regeneration. Med Res Rev, 2016, 10.1002/med.21400.
9. [9] Hare, J.M., Fishman, J.E., Gerstenblith, G., DiFede Velazquez, D.L., Zambrano, J.P., Suncion, V.Y., et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308:22 (2012), 2369–2379.
10. [10] Williams, A.R., Hare, J.M., Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 109:8 (2011), 923–940.
11. [11] Chen, X., Wang, C., Yin, J., Xu, J., Wei, J., Zhang, Y., Efficacy of mesenchymal stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. PLoS ONE, 10(8), 2015 e0136991.
12. [12] Doran, P.M., Cartilage tissue engineering: what have we learned in practice?. Methods Mol Biol 1340 (2015), 3–21.
13. [13] Friedenstein, A.J., Chailakhjan, R.K., Lalykina, K.S., The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet 3:4 (1970), 393–403.
14. [14] Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8:4 (2006), 315–317.
15. [15] Prockop, D.J., Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 17:6 (2009), 939–946.
16. [16] Gnecchi, M., Melo, L.G., Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol 482 (2009), 281–294.
17. [17] Oberbauer, E., Steffenhagen, C., Wurzer, C., Gabriel, C., Redl, H., Wolbank, S., Enzymatic and non-enzymatic isolation systems for adipose tissue-derived cells: current state of the art. Cell Regen (Lond), 4, 2015, 7.
18. [18] Bieback, K., Kluter, H., Mesenchymal stromal cells from umbilical cord blood. Curr Stem Cell Res Ther 2:4 (2007), 310–323.
19. [19] Lam, P.Y.P., Ho, I.A.W., Tumor tropism of mesenchymal stem cells. Shah, K., (eds.) Stem cell therapeutics for cancer, 2013, John Wiley & Sons, Inc, Hoboken, NJ.
20. [20] D'Souza, N., Burns, J.S., Grisendi, G., Candini, O., Veronesi, E., Piccinno, S., et al. MSC and tumors: homing, differentiation, and secretion influence therapeutic potential. Adv Biochem Eng Biotechnol 130 (2013), 209–266.
21. [21] Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:8 (2005), 3307–3318.
22. [22] Sasportas, L.S., Kasmieh, R., Wakimoto, H., Hingtgen, S., van de Water, J.A., Mohapatra, G., et al. Assessmentof therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106:12 (2009), 4822–4827.
23. [23] Dwyer, R.M., Ryan, J., Havelin, R.J., Morris, J.C., Miller, B.W., Liu, Z., et al. Mesenchymal stem cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer. Stem Cells 29:7 (2011), 1149–1157.
24. [24] Kanehira, M., Xin, H., Hoshino, K., Maemondo, M., Mizuguchi, H., Hayakawa, T., et al. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther 14:11 (2007), 894–903.
25. [25] Loebinger, M.R., Eddaoudi, A., Davies, D., Janes, S.M., Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 69:10 (2009), 4134–4142.
26. [26] Sage, E.K., Kolluri, K.K., McNulty, K., Lourenco Sda, S., Kalber, T.L., Ordidge, K.L., et al. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax 69:7 (2014), 638–647.
27. [27] van Poll, D., Parekkadan, B., Cho, C.H., Berthiaume, F., Nahmias, Y., Tilles, A.W., et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 47:5 (2008), 1634–1643.
28. [28] Li, G.C., Ye, Q.H., Xue, Y.H., Sun, H.J., Zhou, H.J., Ren, N., et al. Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line. Cancer Sci 101:12 (2010), 2546–2553.
29. [29] Zielske, S.P., Livant, D.L., Lawrence, T.S., Radiation increases invasion of gene-modified mesenchymal stem cells into tumors. Int J Radiat Oncol Biol Phys 75:3 (2009), 843–853.
30. [30] Kidd, S., Caldwell, L., Dietrich, M., Samudio, I., Spaeth, E.L., Watson, K., et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 12:5 (2010), 615–625.
31. [31] Zischek, C., Niess, H., Ischenko, I., Conrad, C., Huss, R., Jauch, K.W., et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 250:5 (2009), 747–753.
32. [32] Serakinci, N., Christensen, R., Fahrioglu, U., Sorensen, F.B., Dagnaes-Hansen, F., Hajek, M., et al. Mesenchymal stem cells as therapeutic delivery vehicles targeting tumor stroma. Cancer Biother Radiopharm 26:6 (2011), 767–773.
33. [33] Studeny, M., Marini, F.C., Champlin, R.E., Zompetta, C., Fidler, I.J., Andreeff, M., Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:13 (2002), 3603–3608.
34. [34] Khakoo, A.Y., Pati, S., Anderson, S.A., Reid, W., Elshal, M.F., Rovira, I.I., et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 203:5 (2006), 1235–1247.
35. [35] Gao, H., Priebe, W., Glod, J., Banerjee, D., Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Stem Cells 27:4 (2009), 857–865.
36. [36] Komarova, S., Roth, J., Alvarez, R., Curiel, D.T., Pereboeva, L., Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor. J Ovarian Res, 3, 2010, 12.
37. [37] Lourenco, S., Teixeira, V.H., Kalber, T., Jose, R.J., Floto, R.A., Janes, S.M., Macrophage migration inhibitory factor-CXCR4 is the dominant chemotactic axis in human mesenchymal stem cell recruitment to tumors. J Immunol 194:7 (2015), 3463–3474.
38. [38] Phillips, R.J., Burdick, M.D., Lutz, M., Belperio, J.A., Keane, M.P., Strieter, R.M., The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167:12 (2003), 1676–1686.
39. [39] Griffin, M.D., Ryan, A.E., Alagesan, S., Lohan, P., Treacy, O., Ritter, T., Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunol Cell Biol 91:1 (2013), 40–51.
40. [40] Schu, S., Nosov, M., O'Flynn, L., Shaw, G., Treacy, O., Barry, F., et al. Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 16:9 (2012), 2094–2103.
41. [41] Nauta, A.J., Fibbe, W.E., Immunomodulatory properties of mesenchymal stromal cells. Blood 110:10 (2007), 3499–3506.
42. [42] Ryan, A.E., Lohan, P., O'Flynn, L., Treacy, O., Chen, X., Coleman, C., et al. Chondrogenic differentiation increases antidonor immune response to allogeneic mesenchymal stem cell transplantation. Mol Ther 22:3 (2014), 655–667.
43. [43] Huang, X.P., Sun, Z., Miyagi, Y., McDonald Kinkaid, H., Zhang, L., Weisel, R.D., et al. Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. Circulation 122:23 (2010), 2419–2429.
44. [44] Liu, H., Kemeny, D.M., Heng, B.C., Ouyang, H.W., Melendez, A.J., Cao, T., The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J Immunol 176:5 (2006), 2864–2871.
45. [45] Ribeiro, A., Laranjeira, P., Mendes, S., Velada, I., Leite, C., Andrade, P., et al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther, 4(5), 2013, 125.
46. [46] Li, Y., Lin, F., Mesenchymal stem cells are injured by complement after their contact with serum. Blood 120:17 (2012), 3436–3443.
47. [47] Park, J.S., Suryaprakash, S., Lao, Y.H., Leong, K.W., Engineering mesenchymal stem cells for regenerative medicine and drug delivery. Methods 84 (2015), 3–16.
48. [48] Huang, B., Tabata, Y., Gao, J.Q., Mesenchymal stem cells as therapeutic agents and potential targeted gene delivery vehicle for brain diseases. J Control Release 162:2 (2012), 464–473.
49. [49] Young, J.S., Kim, J.W., Ahmed, A.U., Lesniak, M.S., Therapeutic cell carriers: a potential road to cure glioma. Expert Rev Neurother 14:6 (2014), 651–660.
50. [50] Heller, L.C., Ugen, K., Heller, R., Electroporation for targeted gene transfer. Expert Opin Drug Deliv 2:2 (2005), 255–268.
51. [51] Lurquin, P.F., Gene transfer by electroporation. Mol Biotechnol 7:1 (1997), 5–35.
52. [52] Dean, D.A., Machado-Aranda, D., Blair-Parks, K., Yeldandi, A.V., Young, J.L., Electroporation as a method for high-level nonviral gene transfer to the lung. Gene Ther 10:18 (2003), 1608–1615.
53. [53] Hofmann, G.A., Dev, S.B., Nanda, G.S., Rabussay, D., Electroporation therapy of solid tumors. Crit Rev Ther Drug Carrier Syst 16:6 (1999), 523–569.
54. [54] Jiang, J., Yamato, E., Miyazaki, J., Intravenous delivery of naked plasmid DNA for in vivo cytokine expression. Biochem Biophys Res Commun 289:5 (2001), 1088–1092.
55. [55] Maruyama, H., Higuchi, N., Kameda, S., Miyazaki, J., Gejyo, F., Rat liver-targeted naked plasmid DNA transfer by tail vein injection. Mol Biotechnol 26:2 (2004), 165–172.
56. [56] Plank, C., Schillinger, U., Scherer, F., Bergemann, C., Remy, J.S., Krotz, F., et al. The magnetofection method: using magnetic force to enhance gene delivery. Biol Chem 384:5 (2003), 737–747.
57. [57] Knapp, J.E., Liu, D., Hydrodynamic delivery of DNA. Methods Mol Biol 245 (2004), 245–250.
58. [58] Herweijer, H., Wolff, J.A., Progress and prospects: naked DNA gene transfer and therapy. Gene Ther 10:6 (2003), 453–458.
59. [59] De Smedt, S.C., Demeester, J., Hennink, W.E., Cationic polymer based gene delivery systems. Pharm Res 17:2 (2000), 113–126.
60. [60] Ewert, K., Slack, N.L., Ahmad, A., Evans, H.M., Lin, A.J., Samuel, C.E., et al. Cationic lipid-DNA complexes for gene therapy: understanding the relationship between complex structure and gene delivery pathways at the molecular level. Curr Med Chem 11:2 (2004), 133–149.
61. [61] Davis, M.E., Non-viral gene delivery systems. Curr Opin Biotechnol 13:2 (2002), 128–131.
62. [62] Kumari, A., Yadav, S.K., Cellular interactions of therapeutically delivered nanoparticles. Expert Opin Drug Deliv 8:2 (2011), 141–151.
63. [63] Lee, K., Majumdar, M.K., Buyaner, D., Hendricks, J.K., Pittenger, M.F., Mosca, J.D., Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther 3:6 (2001), 857–866.
64. [64] Chan, J., O'Donoghue, K., de la Fuente, J., Roberts, I.A., Kumar, S., Morgan, J.E., et al. Human fetal mesenchymal stem cells as vehicles for gene delivery. Stem Cells 23:1 (2005), 93–102.
65. [65] Hacein-Bey-Abina, S., de Saint Basile, G., Cavazzana-Calvo, M., Gene therapy of X-linked severe combined immunodeficiency. Methods Mol Biol 215 (2003), 247–259.
66. [66] Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348:3 (2003), 255–256.
67. [67] Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Veres, G., Schmidt, M., Kutschera, I., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326:5954 (2009), 818–823.
68. [68] Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467:7313 (2010), 318–322.
69. [69] Aiuti, A., Biasco, L., Scaramuzza, S., Ferrua, F., Cicalese, M.P., Baricordi, C., et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341(6148), 2013, 1233151.
70. [70] Yu, X., Chen, D., Zhang, Y., Wu, X., Huang, Z., Zhou, H., et al. Overexpression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke. J Neurol Sci 316:1–2 (2012), 141–149.
71. [71] Sato, H., Kuwashima, N., Sakaida, T., Hatano, M., Dusak, J.E., Fellows-Mayle, W.K., et al. Epidermal growth factor receptor-transfected bone marrow stromal cells exhibit enhanced migratory response and therapeutic potential against murine brain tumors. Cancer Gene Ther 12:9 (2005), 757–768.
72. [72] Lathrop, M.J., Sage, E.K., Macura, S.L., Brooks, E.M., Cruz, F., Bonenfant, N.R., et al. Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma. Cancer Gene Ther 22:1 (2015), 44–54.
73. [73] Studeny, M., Marini, F.C., Dembinski, J.L., Zompetta, C., Cabreira-Hansen, M., Bekele, B.N., et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:21 (2004), 1593–1603.
74. [74] Ren, C., Kumar, S., Chanda, D., Kallman, L., Chen, J., Mountz, J.D., et al. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther 15:21 (2008), 1446–1453.
75. [75] Chen, X.C., Wang, R., Zhao, X., Wei, Y.Q., Hu, M., Wang, Y.S., et al. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis 27:12 (2006), 2434–2441.
76. [76] Chen, X., Lin, X., Zhao, J., Shi, W., Zhang, H., Wang, Y., et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol Ther 16:4 (2008), 749–756.
77. [77] Li, X., Lu, Y., Huang, W., Xu, H., Chen, X., Geng, Q., et al. In vitro effect of adenovirus-mediated human Gamma Interferon gene transfer into human mesenchymal stem cells for chronic myelogenous leukemia. Hematol Oncol 24:3 (2006), 151–158.
78. [78] Mei, S.H., McCarter, S.D., Deng, Y., Parker, C.H., Liles, W.C., Stewart, D.J., Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med, 4(9), 2007 e269.
79. [79] Kanki-Horimoto, S., Horimoto, H., Mieno, S., Kishida, K., Watanabe, F., Furuya, E., et al. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation, 114(Suppl. 1), 2006 I181–5.
80. [80] Matsumoto, R., Omura, T., Yoshiyama, M., Hayashi, T., Inamoto, S., Koh, K.R., et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol 25:6 (2005), 1168–1173.
81. [81] Cancer Research UK, Cancer Statistics for the UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics#heading-Zero accessed 09.08.16.
82. [82] Eliopoulos, N., Francois, M., Boivin, M.N., Martineau, D., Galipeau, J., Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Res 68:12 (2008), 4810–4818.
83. [83] Hu, M., Yang, J.L., Teng, H., Jia, Y.Q., Wang, R., Zhang, X.W., et al. Anti-angiogenesis therapy based on the bone marrow-derived stromal cells genetically engineered to express sFlt-1 in mouse tumor model. BMC Cancer, 8, 2008, 306.
84. [84] Zolochevska, O., Yu, G., Gimble, J.M., Figueiredo, M.L., Pigment epithelial-derived factor and melanoma differentiation associated gene-7 cytokine gene therapies delivered by adipose-derived stromal/mesenchymal stem cells are effective in reducing prostate cancer cell growth. Stem Cells Dev 21:7 (2012), 1112–1123.
85. [85] Xiang, J., Tang, J., Song, C., Yang, Z., Hirst, D.G., Zheng, Q.J., et al. Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy 11:5 (2009), 516–526.
86. [86] Vivo, C., Liu, W., Broaddus, V.C., c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 278:28 (2003), 25461–25467.
87. [87] Broaddus, V.C., Dansen, T.B., Abayasiriwardana, K.S., Wilson, S.M., Finch, A.J., Swigart, L.B., et al. Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage. J Biol Chem 280:13 (2005), 12486–12493.
88. [88] Li, L., Thomas, R.M., Suzuki, H., De Brabander, J.K., Wang, X., Harran, P.G., A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305:5689 (2004), 1471–1474.
89. [89] Reagan, M.R., Seib, F.P., McMillin, D.W., Sage, E.K., Mitsiades, C.S., Janes, S.M., et al. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. J Breast Cancer 15:3 (2012), 273–282.
90. [90] Grisendi, G., Bussolari, R., Cafarelli, L., Petak, I., Rasini, V., Veronesi, E., et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res 70:9 (2010), 3718–3729.
91. [91] Ciavarella, S., Grisendi, G., Dominici, M., Tucci, M., Brunetti, O., Dammacco, F., et al. In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. Br J Haematol 157:5 (2012), 586–598.
92. [92] Zhang, J., Hou, L., Wu, X., Zhao, D., Wang, Z., Hu, H., et al. Inhibitory effect of genetically engineered mesenchymal stem cells with Apoptin on hepatoma cells in vitro and in vivo. Mol Cell Biochem 416:1–2 (2016), 193–203.
93. [93] Altanerova, V., Cihova, M., Babic, M., Rychly, B., Ondicova, K., Mravec, B., et al. Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma. Int J Cancer 130:10 (2012), 2455–2463.
94. [94] Alieva, M., Bago, J.R., Aguilar, E., Soler-Botija, C., Vila, O.F., Molet, J., et al. Glioblastoma therapy with cytotoxic mesenchymal stromal cells optimized by bioluminescence imaging of tumor and therapeutic cell response. PLoS ONE, 7(4), 2012 e35148.
95. [95] Ashkenazi, A., Pai, R.C., Fong, S., Leung, S., Lawrence, D.A., Marsters, S.A., et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:2 (1999), 155–162.
96. [96] Tsao, A.S., Kim, E.S., Hong, W.K., Chemoprevention of cancer. CA Cancer J Clin 54:3 (2004), 150–180.
97. [97] Einhorn, S., Grander, D., Why do so many cancer patients fail to respond to interferon therapy?. J Interferon Cytokine Res 16:4 (1996), 275–281.
98. [98] Bocci, V., Carraro, F., Naldini, A., Borrelli, E., Biagi, G., Gotti, G., et al. Interferon levels in human pulmonary tumors are lower than plasma levels. J Biol Regul Homeost Agents 4:4 (1990), 153–156.
99. [99] Wilson, J.G., Liu, K.D., Zhuo, H., Caballero, L., McMillan, M., Fang, X., et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3:1 (2015), 24–32.
100. [100] Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA Cancer J Clin 64:1 (2014), 9–29.
101. [101] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144:5 (2011), 646–674.
102. [102] Hofmeister, V., Schrama, D., Becker, J.C., Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 57:1 (2008), 1–17.
103. [103] Niess, H., Bao, Q., Conrad, C., Zischek, C., Notohamiprodjo, M., Schwab, F., et al. Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg 254:5 (2011), 767–774 discussion 74-5.
104. [104] Niess, H., von Einem, J.C., Thomas, M.N., Michl, M., Angele, M.K., Huss, R., et al. Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial. BMC Cancer, 15, 2015, 237.
105. [105] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA Cancer J Clin 61:2 (2011), 69–90.
106. [106] Collaborative, N., sCLC. Chemotherapy in non-small cell lung cancer; a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995), 899–909.
107. [107] Wiley, S.R., Schooley, K., Smolak, P.J., Din, W.S., Huang, C.P., Nicholl, J.K., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:6 (1995), 673–682.
108. [108] Prockop, D.J., Brenner, M., Fibbe, W.E., Horwitz, E., Le Blanc, K., Phinney, D.G., et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy 12:5 (2010), 576–578.
109. [109] Yuan, Z., Lourenco Sda, S., Sage, E.K., Kolluri, K.K., Lowdell, M.W., Janes, S.M., Cryopreservation of human mesenchymal stromal cells expressing TRAIL for human anti-cancer therapy. Cytotherapy 18:7 (2016), 860–869.
110. [110] Galipeau, J., Krampera, M., Barrett, J., Dazzi, F., Deans, R.J., DeBruijn, J., et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 18:2 (2016), 151–159.
111. [111] Bindslev, L., Haack-Sorensen, M., Bisgaard, K., Kragh, L., Mortensen, S., Hesse, B., et al. Labelling of human mesenchymal stem cells with indium-111 for SPECT imaging: effect on cell proliferation and differentiation. Eur J Nucl Med Mol Imaging 33:10 (2006), 1171–1177.
112. [112] Chin, B.B., Nakamoto, Y., Bulte, J.W., Pittenger, M.F., Wahl, R., Kraitchman, D.L., 111In oxine labelled mesenchymal stem cell SPECT after intravenous administration in myocardial infarction. Nucl Med Commun 24:11 (2003), 1149–1154.
113. [113] Chen, Q., Cheng, P., Yin, T., He, H., Yang, L., Wei, Y., et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma. Int J Mol Med 30:3 (2012), 527–534.
114. [114] Yan, C., Song, X., Yu, W., Wei, F., Li, H., Lv, M., et al. Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects. Tumor Biol 37:6 (2016), 8425–8435.
115. [115] Amano, S., Li, S., Gu, C., Gao, Y., Koizumi, S., Yamamoto, S., et al. Use of genetically engineered bone marrow-derived mesenchymal stem cells for glioma gene therapy. Int J Oncol 35:6 (2009), 1265–1270.
116. [116] Kim, S.M., Oh, J.H., Park, S.A., Ryu, C.H., Lim, J.Y., Kim, D.S., et al. Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy. Stem Cells 28:12 (2010), 2217–2228.
117. [117] Wu, N., Zhang, Y.L., Wang, H.T., Li, D.W., Dai, H.J., Zhang, Q.Q., et al. Overexpression of hepatocyte nuclear factor 4alpha in human mesenchymal stem cells suppresses hepatocellular carcinoma development through Wnt/beta-catenin signaling pathway downregulation. Cancer Biol Ther 17:5 (2016), 558–565.
118. [118] Xie, C., Xie, D.Y., Lin, B.L., Zhang, G.L., Wang, P.P., Peng, L., et al. Interferon-beta gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway. Br J Cancer 109:5 (2013), 1198–1205.
119. [119] Han, J., Zhao, J., Xu, J., Wen, Y., Mesenchymal stem cells genetically modified by lentivirus-mediated interleukin-12 inhibit malignant ascites in mice. Exp Ther Med 8:4 (2014), 1330–1334.
120. [120] Kim, N., Nam, Y.S., Im, K.I., Lim, J.Y., Lee, E.S., Jeon, Y.W., et al. IL-21-expressing mesenchymal stem cells prevent lethal B-Cell lymphoma through efficient delivery of IL-21, which redirects the immune system to target the tumor. Stem Cells Dev 24:23 (2015), 2808–2821.
121. [121] Wang, G.X., Zhan, Y.A., Hu, H.L., Wang, Y., Fu, B., Mesenchymal stem cells modified to express interferon-beta inhibit the growth of prostate cancer in a mouse model. J Int Med Res 40:1 (2012), 317–327.